Kala Pharmaceuticals Inc (NASDAQ:KALA) Has Decline in Shorts

... which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase ...

source https://cardinalweekly.com/kala-pharmaceuticals-inc-nasdaqkala-has-decline-in-shorts/